2018 Press Releases | Media | Grünenthal Group

Discover Grünenthal

12/14/2018

Aachen, Germany and Gothenburg, Sweden, 14 December 2018 – Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis’ technology for prescription medicines in all pain related indications. The agreement also entails an option for Grünenthal to an exclusive worldwide license to the technology in these indications. The handheld device enables individualised dosing of oral medicines in micro units, provides support for patient compliance, can be combined with digital solutions and thus significantly improves patients’ safety. The agreement with Grünenthal, a leading pain specialist, is the first partnering deal for life science startup OnDosis on their innovative technology. While this agreement covers the indication area pain; other focus areas of OnDosis, like ADHD and immunosuppression, remain available for further cooperation with third parties.

12/7/2018

Aachen, Germany, December 7, 2018 – Grünenthal is participating in the PAIN-Vis research initiative and working with the University of Cologne, the Goethe University Frankfurt and Forschungszentrum Jülich [Jülich Research Center] to create a foundation for improvements in pain diagnosis. The basic research project will receive €2.26 million from the European Regional Development Fund and the German federal state of North Rhine-Westphalia over three years from 2017 to 2020 (PAIN-Vis grant ref. EFRE-800975).

12/3/2018

Aachen, Germany, 03 December 2018 – Grünenthal today announced the successful completion of its acquisition of European rights to Nexium and global (ex US and Japan) rights to Vimovo from AstraZeneca for a total consideration of up to US$ 922 m (€ 811 m). “Today is an important day for Grünenthal,” said Gabriel Baertschi, CEO Grünenthal. “This transaction represents a significant step towards our vision of creating a world free of pain for patients. It is also is the biggest single investment in the history of our company. This transaction will double our EBITDA performance and significantly strengthen our leading position in pain management”.

11/14/2018

Aachen, Germany / Morristown, New Jersey, USA, 14 November, 2018 – Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics.

11/5/2018

Aachen, Germany, 5 November 2018 – Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza® (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grünenthal is now the sole owner of Qutenza® worldwide, including the US, Latin America, Asia and Australia. Grünenthal had already acquired exclusive commercial rights for Europe, Middle East and Africa in December 2016.

10/30/2018

Aachen, Germany, 30 October 2018 – Grünenthal today announced that it has agreed to acquire AstraZeneca’s European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m (€ 811 m). Nexium (esomeprazole) is a proton pump inhibitor (PPI) that helps to reduce the amount of acid produced by the stomach in patients with gastroesophageal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). Vimovo is a fixed-dose combination tablet of naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium. It is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric and/or duodenal ulcers.

10/10/2018

Aachen, Deutschland, 9. Oktober 2018 – Kerstin Nacken hat am 1. September 2018 die neu geschaffene Position “Head Editorial Management and Media Relations“ bei Grünenthal übernommen. Sie verantwortet damit die Medienarbeit des forschenden Pharmaunternehmens und die Redaktion aller internen und externen Kanäle der globalen Unternehmenskommunikation.

10/10/2018

Aachen, Germany, 9 October 2018 – Kerstin Nacken took over the newly created position "Head Editorial Management and Media Relations" at Grünenthal on 1 September 2018. In this function she is responsible for all media related activities of the research-based pharmaceutical company and heads the editorial team for internal and external corporate channels.

8/28/2018

Aachen, Germany, 28 August 2018 – Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of hyperuricaemia in adult gout patients who have not been able to reach target levels of uric acid serum with a dose of allopurinol alone. Lesinurad is the first innovative uricosuric in gout treatment for over 40 years.

8/21/2018

Aachen, 21. August 2018 – 27 junge Menschen haben ihre Berufsausbildung bei Grünenthal begonnen. Das international tätige Pharmaunternehmen ist seit über sechzig Jahren in der Städteregion Aachen verwurzelt und einer der größten Ausbildungsunternehmen für kaufmännische und naturwissenschaftliche Berufe in der Region.

Štěpán Kráčala, Head Global Communications, Grünenthal

Štěpán Kráčala

Head Global Communications


Grünenthal GmbH

52099

Germany


Phone +49 241 569-1335

E-Mail Stepan.Kracala@grunenthal.com

 
External Link:
You are now leaving the Grünenthal Group website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites. ... Cancel ... Ok